Amgen will buy Micromet for $1.16 billion

01/26/2012 | Genetic Engineering & Biotechnology News

Amgen's acquisition of Micromet for $11 a share was approved by the boards of both companies. The cash transaction, worth about $1.16 billion, gives Amgen access to Micromet's antibody technology Bispecific T-cell Engager and its blood cancer drug candidate blinatumomab.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA